Section of Neurology - Dr. James J. Marriott

Assistant Professor, Department of Internal Medicine (Neurology), University of Manitoba.

Degrees: MD, MSc, FRCPC

Mailing Address: Health Sciences Centre, GF543, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9

Tel: (204) 787-4951; Fax: (204) 787-1486


Clinical Interests:
My clinical interests are focused on the care of patients with multiple sclerosis (MS).

Research Interests:
My research interests revolve around clinical trials to develop new disease-modifying and symptomatic therapies for MS patients.  I am specifically interested in investigator-initiated trials to study novel agents to treat symptoms such as MS-related fatigue.  I am also interested in clinical trial design and developing better endpoints for evaluating MS disability.  In addition, I am interesting in how clinical trial data is incorporated into general medical practice.
Recent Publications:

Original Papers
Marriott J, Miyasaki J, Gronseth G, O’Connor P.  Evidence Report:  The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis (an evidence-based review).  Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology 2010; 74:1463-1470.

Marriott J, Mamdani M, Saposnik G, Gomes T, Manno M, O’Connor PW.  Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario. Canadian Journal of Neurological Sciences [in press].

Evans C, Beland S-G, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jetté N, Pringsheim T, Marrie RA.  Incidence and prevalence of multiple sclerosis in the Americas: a systematic review.  Neuroepidemiology [in press].

Invited Editorials
Marriott J, O’Connor P.  Lessons learned from long-term MS treatment trials.  Multiple Sclerosis 2010; 16:1028-1030.

Review Papers
Marriott J, O’Connor P.  Emerging therapies in relapsing-remitting multiple sclerosis. Reviews on Recent Clinical Trials 2010; 5:179-188.

Marriott J.  Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients.  Journal of Central Nervous System Disease 2011; 3:1-8.

Marriott J, O’Connor P.  Definitions of Breakthrough Disease and Second-Line Agents.  Neurologic Clinics 2011; 29:411-422.

Book Chapters
Marriott J, O’Connor P.  Immunosuppression.  In:  Putzki N, Hartung H-P, editors.  Treatment of Multiple Sclerosis.  Bremen:  Uni-Med Verlag AG; 2009. p. 45-57.

Marriott J, O’Connor P.  Differential Diagnosis and Diagnosis Criteria for Multiple Sclerosis:  Application and Pitfalls.  In:  Lucchinetti C, Hohlfeld R, editors.  Multiple Sclerosis 3.  Philadelphia PA:  Saunders Elsevier; 2010.